Regulatory Focus™ > News Articles > New Guidance on Conflict of Interest Disclosures for Advisory Committees

New Guidance on Conflict of Interest Disclosures for Advisory Committees

Posted 08 March 2012 | By Alexander Gaffney, RAC 

The US Food and Drug Administration (FDA) released new draft guidance on 8 March about the availability of conflict of interest information and waiver information for members of advisory committees.

The guidance also establishes a procedure for disclosing financial interest and granting conflict-of-interest (COI) waivers to special Government employees (SGEs) and regular employees. The guidance also provides a standardized mechanism for public disclosure of such documents.


Read more:

FDA - Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers

Federal Register - Guidance for the Public, Advisory Committee Members, and Staff; Availability: Advisory Committee Members' Financial Interest Information and Waivers


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe